Literature DB >> 19276181

Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.

Feng Jiang1, Qi Qiu, Abha Khanna, Nevins W Todd, Janaki Deepak, Lingxiao Xing, Huijun Wang, Zhenqiu Liu, Yun Su, Sanford A Stass, Ruth L Katz.   

Abstract

Tumor contains small population of cancer stem cells (CSC) that are responsible for its maintenance and relapse. Analysis of these CSCs may lead to effective prognostic and therapeutic strategies for the treatment of cancer patients. We report here the identification of CSCs from human lung cancer cells using Aldefluor assay followed by fluorescence-activated cell sorting analysis. Isolated cancer cells with relatively high aldehyde dehydrogenase 1 (ALDH1) activity display in vitro features of CSCs, including capacities for proliferation, self-renewal, and differentiation, resistance to chemotherapy, and expressing CSC surface marker CD133. In vivo experiments show that the ALDH1-positive cells could generate tumors that recapitulate the heterogeneity of the parental cancer cells. Immunohistochemical analysis of 303 clinical specimens from three independent cohorts of lung cancer patients and controls show that expression of ALDH1 is positively correlated with the stage and grade of lung tumors and related to a poor prognosis for the patients with early-stage lung cancer. ALDH1 is therefore a lung tumor stem cell-associated marker. These findings offer an important new tool for the study of lung CSCs and provide a potential prognostic factor and therapeutic target for treatment of the patients with lung cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276181      PMCID: PMC4255559          DOI: 10.1158/1541-7786.MCR-08-0393

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  35 in total

Review 1.  Focus on lung cancer.

Authors:  John D Minna; Jack A Roth; Adi F Gazdar
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

Review 2.  Applying the principles of stem-cell biology to cancer.

Authors:  Ricardo Pardal; Michael F Clarke; Sean J Morrison
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

3.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

Review 4.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

Review 5.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

6.  Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents.

Authors:  L Sreerama; N E Sladek
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

7.  Comparison of molecular abnormalities in bronchial brushings and tumor touch preparations.

Authors:  Güliz A Barkan; Nancy P Caraway; Feng Jiang; Tanweer M Zaidi; Ricardo Fernandez; Ara Vaporcyin; Rodolfo Morice; Xian Zhou; Benjamin Nebiyou Bekele; Ruth L Katz
Journal:  Cancer       Date:  2005-02-25       Impact factor: 6.860

8.  Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity.

Authors:  Lyle Armstrong; Miodrag Stojkovic; Ian Dimmick; Sajjad Ahmad; Petra Stojkovic; Nicholas Hole; Majlinda Lako
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

9.  CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer.

Authors:  W Hilbe; S Dirnhofer; F Oberwasserlechner; T Schmid; E Gunsilius; G Hilbe; E Wöll; C M Kähler
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

10.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Authors:  Christophe Ginestier; Min Hee Hur; Emmanuelle Charafe-Jauffret; Florence Monville; Julie Dutcher; Marty Brown; Jocelyne Jacquemier; Patrice Viens; Celina G Kleer; Suling Liu; Anne Schott; Dan Hayes; Daniel Birnbaum; Max S Wicha; Gabriela Dontu
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

View more
  343 in total

1.  Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas.

Authors:  Benito Campos; Franz-Simon Centner; Justo Lorenzo Bermejo; Ramadan Ali; Katharina Dorsch; Feng Wan; Jörg Felsberg; Rezvan Ahmadi; Niels Grabe; Guido Reifenberger; Andreas Unterberg; Jürgen Burhenne; Christel Herold-Mende
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer.

Authors:  Crystal J Hessman; Emily J Bubbers; Kevin G Billingsley; Daniel O Herzig; Melissa H Wong
Journal:  Am J Surg       Date:  2012-03-09       Impact factor: 2.565

3.  Aldehyde dehydrogenase 3B1 (ALDH3B1): immunohistochemical tissue distribution and cellular-specific localization in normal and cancerous human tissues.

Authors:  Satori A Marchitti; David J Orlicky; Chad Brocker; Vasilis Vasiliou
Journal:  J Histochem Cytochem       Date:  2010-09       Impact factor: 2.479

Review 4.  Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.

Authors:  Qin Pan; Qiao Li; Shuang Liu; Ning Ning; Xiaolian Zhang; Yingxin Xu; Alfred E Chang; Max S Wicha
Journal:  Stem Cells       Date:  2015-05-13       Impact factor: 6.277

5.  All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.

Authors:  Wenxiu Yao; Liyang Wang; Huan Huang; Xin Li; Pinjia Wang; Kun Mi; Jia Cheng; Huifen Liu; Cuirong Gu; Lingxiao Huang; Jianming Huang
Journal:  BMC Cancer       Date:  2020-04-15       Impact factor: 4.430

6.  Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma.

Authors:  Xinwei Yun; Keqiang Zhang; Jinhui Wang; Rajendra P Pangeni; Lu Yang; Melissa Bonner; Jun Wu; Jami Wang; Isaac K Nardi; Ming Gao; Dan J Raz
Journal:  Mol Cancer Res       Date:  2018-05-02       Impact factor: 5.852

7.  ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.

Authors:  J A Ajani; X Wang; S Song; A Suzuki; T Taketa; K Sudo; R Wadhwa; W L Hofstetter; R Komaki; D M Maru; J H Lee; M S Bhutani; B Weston; V Baladandayuthapani; Y Yao; S Honjo; A W Scott; H D Skinner; R L Johnson; D Berry
Journal:  Mol Oncol       Date:  2013-10-28       Impact factor: 6.603

Review 8.  Lung stem and progenitor cells in tissue homeostasis and disease.

Authors:  Kristen T Leeman; Christine M Fillmore; Carla F Kim
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

9.  Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.

Authors:  Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Antonio Segura-Carretero; Jorge Joven; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Cell Cycle       Date:  2013-09-17       Impact factor: 4.534

10.  Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma.

Authors:  Kefeng Wang; Xiaonan Chen; Yunhong Zhan; Weiguo Jiang; Xuefeng Liu; Xia Wang; Bin Wu
Journal:  Med Oncol       Date:  2013-04-13       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.